The Impact of Censoring Drug Switching in Medication Adherence Measures of Chronic Single Ingredient Oral Drugs.
We explored how drug switching impacts adherence measures for common chronic oral medications. Switching between ingredients with the same indication was detected within a 30-day grace period. The proportion of days covered (PDC) and adherent status (cutoff 0.8) for each ingredient was calculated and compared between different censoring approaches: censoring drug switching (PDCswitch), censoring the end of dispensing (PDCend), and fixed 365-day period (PDC365). Overall, 854,380 (15.9%) patients in the Optum ClinFormatics (Optum) and 150,785 (22.0%) patients in the MarketScan Multi-state Medicaid (MDCD) had at least one switch within one year. Compared with PDC365 in Optum, PDCswitch means were higher: 0.85 vs. 0.41 for antihypertensive, 0.82 vs. 0.46 for antihyperglycemics, and 0.84 vs. 0.33 for antihyerlipidemia. Further, the percentages of adherent patients were higher: 95.8% vs. 17.9% for antihypertensive, 85.5% vs. 18.9% for antihyperglycemics, and 72.1% vs. 5.3% for antihyerlipidemia. Significant and modest changes were observed between PDCswitch and PDCend.